Oriderma
Natural health product licensed in Canada
- Licence holder
- Orimed Pharma Inc.
- NPN or DIN-HM
- 80044074
- Status
- Active licence
- Licence date
- 8 August 2013
- Revision date
- Not provided
- Form
- Onguent
- Route of administration
- Topique
- Application type
- Officinale
Oral dose analysis does not apply without an established exclusively oral route.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Jus en poudre de feuille d'Aloe Barbadensis, Huile de foie de morue, Huile minérale, Paraffine dure, Extrait floral de Lavandula Angustifolia (Lavande), Lanoline, Aqua, Pétrolatum blanc, Extrait de Boswellia Serrata
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Sous-population S/O | Not specified | Not specified | Not specified |
Uses authorised in Canada
Dries the oozing and weeping and helps relieve minor skin irritation and itching due to poison ivy, poison oak and poison sumac.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
For external use only. Avoid contact with eyes. Consult a healthcare practitioner if symptoms worsen or last for more than 7 days.
Source
Official Health Canada record, licence 80044074
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.